BioSpace News Archive

Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today outlined the global development strategy for its lead gene therapy candidate, ETX101, for the treatment of SCN1A+ Dravet syndrome.

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024.

Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent’s lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO) today announced that management will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th – 14th.

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually.

Theratechnologies Inc. announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.

Genprex, Inc. today announced that its Chief Financial Officer, Ryan Confer will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference.

Lavior Pharma is on a mission to address health disparities affecting African Americans, who are 60% more likely to be diagnosed with diabetes and three times more likely to undergo amputation as a result.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala.

Rentschler Biopharma SE, a leading contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, announced that Senta Brandt has been promoted to the global position of Head of Transformation, effective January 1, 2024.